Department of Pharmacy, Institute of Cancerology Gustave Roussy, University of Paris-Sud, Villejuif, France.
Thyroid. 2012 Jan;22(1):59-63. doi: 10.1089/thy.2010.0406. Epub 2011 Dec 2.
Thyroid cancer patients treated with radioiodine are potential source of radiation exposure for other individuals. Thus, we evaluated the radiation dose received by family members of thyroid cancer patients treated with (131)I after hospital discharge.
Seventy-six family members of 56 thyroid cancer patients were included in the study. Thyroid cancer patients were given 3.7 GBq of (131)I and remained in a radiation protection ward for 3 days. Radiation protection recommendations were given to patients and relatives. Life conditions were recorded and radiation doses were monitored using a personal dosimeter.
At discharge, the mean residual activity was 188 MBq. The mean radiation dose delivered to relatives during the 7 days after discharge was low (51.5 μSv) and was similar with either recombinant human thyrotropin (rhTSH) (59 μSv) or withdrawal (50 μSv) (p = 0.37).
With our current practice, radiation doses to relatives are low and well below international recommendations.
接受放射性碘治疗的甲状腺癌患者可能成为其他个体的辐射源。因此，我们评估了甲状腺癌患者在出院后接受（131）I 治疗后其家庭成员所接受的辐射剂量。
本研究纳入了 56 例甲状腺癌患者的 76 名家庭成员。甲状腺癌患者接受 3.7GBq 的（131）I 治疗，并在辐射防护病房中停留 3 天。向患者及其亲属提供了辐射防护建议。记录生活条件，并使用个人剂量计监测辐射剂量。
出院时，平均残余活度为 188MBq。出院后 7 天内亲属接受的平均辐射剂量较低（51.5μSv），与重组人促甲状腺激素（rhTSH）（59μSv）或停药（50μSv）相似（p=0.37）。
根据我们目前的实践，亲属所接受的辐射剂量较低，远低于国际建议。
